Bayer Taps Melissa Joan Hart for Lynkuet Push as Pipeline, Plant and Courtroom Each Run on Their Own Clock
Published on 10/13/2026 at 02:50 | Editorial boerse-global.de
Bayer has enlisted actress Melissa Joan Hart to front a patient-education drive around Lynkuet, its prescription menopause therapy. The partnership, unveiled Friday, puts the spotlight on how the drugmaker talks to women about treatment rather than on any change to its regulatory or commercial footprint.
Lynkuet's active ingredient is elinzanetant, and the medication is approved for moderate-to-severe hot flashes associated with menopause. Pairing a familiar television face with the brand is a communications play — one that raises awareness of an existing product but leaves the bigger questions hanging over Bayer's pharmaceutical franchise and its Roundup litigation untouched.
That distinction matters for anyone weighing the stock. A public-awareness tie-up operates on a different plane than an FDA filing or a factory build. Treating all three as interchangeable signs of momentum muddles what is actually a set of initiatives moving at very different speeds.
Regulatory Steps, Not Approvals
Take Finerenon, marketed as Kerendia. The FDA has accepted Bayer's supplemental application covering adults with chronic kidney disease who do not have diabetes, a filing built on data from the Phase III FIND-CKD trial. Acceptance opens the review door; it does not swing it open. No approval for that expanded patient group can be read into the agency's decision to take up the paperwork.
Should investors sell immediately? Or is it worth buying Bayer?
On the manufacturing side, Bayer disclosed roughly two weeks ago that it will sink USD 2.2 billion into a new pharmaceutical production site in New Albany, Ohio, a project expected to generate about 600 permanent positions. The first module is slated to be operational in 2031, with the second following in 2034 — a timeline that makes clear this is a multi-year capacity build, not a switch that has already been flipped.
Bayer also named Dr. Christoph Koenen as Chief Medical Officer effective October 1. He takes charge of the medical and scientific strategy for the pharma division, placing the appointment squarely in the area where the company is pursuing its next wave of development.
JPMorgan Flags a Soft Third Quarter
Against that strategic backdrop, JPMorgan kept its "Overweight" rating on Bayer with a EUR 61 price target, a call issued about two weeks ago. Analyst Richard Vosser paired the rating with a caution: early expectations for the third quarter look too optimistic. His reasoning centered on timing-related effects in the agricultural business, while he saw little reason to move his full-year estimates. The note effectively separates a possible soft patch in a single quarter from the longer earnings arc.
The next hard data point arrives November 3, when Bayer reports third-quarter 2026 results at 07:30 CET, followed by its quarterly earnings call at 14:00 CET. That release — not the awareness campaign, the FDA acceptance or the Ohio groundbreaking — will show whether the more measured quarterly view holds up.
Bayer at a turning point? This analysis reveals what investors need to know now.
Missouri Testimony Keeps Roundup in the Frame
Running alongside the pharma news is a Roundup case in Missouri, where an oncologist testified Thursday that the herbicide caused the blood cancers afflicting three plaintiffs, according to media accounts. The suit raises allegations touching on product design and product safety.
That testimony is a witness's position in an ongoing proceeding, not a judicial finding. Keeping that line clear is essential when sizing up Bayer's news flow: the Lynkuet partnership speaks to how a medicine is communicated. It answers neither the regulatory questions surrounding other compounds nor the liability questions that Roundup continues to pose.
Ad
Bayer Stock: New Analysis - 13 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
